APLS David O Watson sells $128K worth of shares
Feb 01, 2026, 5:36 AM
0.00%
What does APLS do
Apellis Pharmaceuticals, based in Waltham, Massachusetts, specializes in developing therapies for diseases with high unmet needs, employing 702 staff since its IPO in November 2017. Its approved products include SYFOVRE for geographic atrophy and pegcetacoplan for paroxysmal nocturnal hemoglobinuria.
David O Watson sold 5,780 shares of APLS on 13 January at $22.19 per share, worth a total of $128K. They now own 98,838 APLS shares, or a 6% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
